In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2

• Published in: Journal of experimental pharmacology Vol. 10; pp. 1 - 7
• Main Authors: Jamil, Khurram, Pappas, Stephen Chris, Devarakonda, Krishna R
• Format: Journal Article
• Language: English
• Published: Macclesfield Taylor & Francis Ltd 2018; Dove Medical Press
• Subjects: Binding sites; Gastroenterology; hormones; in vitro techniques; Original Research; Pappas, Chris; Peptides; Pharmaceuticals; pharmacology; terlipressin; vasopressins; United States > US
• ISSN: 1179-1454; 1179-1454
• DOI: 10.2147/JEP.S146034

Terlipressin, a synthetic, systemic vasoconstrictor with selective activity at ­vasopressin-1 (V1) receptors, is a pro-drug for the endogenous/natural porcine hormone [Lys8]-vasopressin (LVP). We investigated binding and receptor-mediated cellular activities of terlipressin, LVP, and endogenous human hormone [Arg8]-vasopressin (AVP) at V1 and vasopressin-2 (V2) receptors. Cell membrane homogenates of Chinese hamster ovary cells expressing human V1 and V2 receptors were used in competitive binding assays to measure receptor-binding activity. These cells were used in functional assays to measure receptor-mediated cellular activity of terlipressin, LVP, and AVP. Binding was measured by [3H]AVP counts, and the activity was measured by fluorometric detection of intracellular calcium mobilization (V1) and cyclic adenosine monophosphate (V2). Binding potency at V1 and V2 was AVP>LVP>>terlipressin. LVP and terlipressin had approximately sixfold higher affinity for V1 than for V2. Cellular activity potency was also AVP>LVP>>terlipressin. Terlipressin was a partial agonist at V1 and a full agonist at V2; LVP was a full agonist at both V1 and V2. The in vivo response to terlipressin is likely due to the partial V1 agonist activity of terlipressin and full V1 agonist activity of its metabolite, LVP. These results provide supportive evidence for previous findings and further establish terlipressin pharmacology for vasopressin receptors.